41 Results

People

  1. Landgren
    Landgren
  2. Shah
    Shah
  3. Giralt
    Giralt
  4. Lesokhin
    Lesokhin
  5. Landau
    Landau
  6. Chung
    Chung
  7. Hassoun
    Hassoun
  8. Korde
    Korde
  9. Mailankody
    Mailankody
  10. Hultcrantz
    Hultcrantz

Groups

  1. Bone Marrow Transplant (41)
  2. Center for Hematologic Malignancies (41)
  3. Department of Medicine (41)
  4. Hematologic Malignancies Research (41)
  5. Hematologic Malignancies, Division of (41)
  6. Myeloma (41)
  7. Survivorship Research (41)
  8. Epidemiology and Biostatistics (29)
  9. Biostatistics Service (27)
  10. CTCR Scholars (27)
  1. "Hematologic Malignancies Research"
  2. "Center for Hematologic Malignancies"
  3. "Gunjan Shah"
  4. "Carl Landgren"
Formats
  1. Meeting Abstract (28)
  2. Journal Article (11)
  3. Research Letter (2)
Groups
  1. Bone Marrow Transplant (41)
  2. Center for Hematologic Malignancies (41)
  3. Department of Medicine (41)
  4. Hematologic Malignancies Research (41)
  5. Hematologic Malignancies, Division of (41)
  6. Myeloma (41)

More Groups

People
  1. Carl Landgren (41)
  2. Gunjan Shah (41)
  3. Sergio Giralt (40)
  4. Alexander Lesokhin (37)
  5. Heather Landau (35)
  6. David Chung (34)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (4)
  4. 2020 (11)
  5. 2019 (7)
  6. 2018 (6)

More Years

Publications
  1. Blood (16)
  2. Biology of Blood and Marrow Transplantation (10)
  3. Clinical Lymphoma, Myeloma and Leukemia (6)
  4. Leukemia and Lymphoma (2)
  5. American Journal of Hematology (1)
  6. Blood Cancer Journal (1)

More Publications

Publishers
  1. American Society of Hematology (16)
  2. Elsevier Inc. (16)
  3. Nature Publishing Group (3)
  4. Taylor & Francis Group (2)
  5. American Medical Association (1)
  6. American Society of Clinical Oncology (1)

More Publishers

Results (41)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A whole foods plant-based weight loss intervention improves quality of life, metabolic, microbiome and immune profile in MGUS/SMM as well as progression trajectory in a subset - the Nutrivention trial
    Meeting Abstract

    Shah, U. A.; Castro, F.; Derkach, A.; Fei, T.; Hosszu, K. K.; McAvoy, D.; DeWolf, S.; Cross, J.; Gradissimo, A.; Nwankwo, A.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • GPRC5D-targeted CAR T cells for myeloma
    Journal Article

    Mailankody, S.; Devlin, S. M.; Landa, J.; Nath, K.; Diamonte, C.; Carstens, E. J.; Russo, D.; Auclair, R.; Fitzgerald, L.; Cadzin, B.; more...
    New England Journal of Medicine (2022)

    Fulltext@MSK | Save
  • Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients
    Meeting Abstract

    Hevroni, G.; Mastey, D.; Tavitian, E.; Derkach, A.; Salcedo, M.; Mailankody, S.; Hassoun, H.; Lesokhin, A. M.; Smith, E. L.; Hultcrantz, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Sustained minimal residual disease negativity in multiple myeloma is impacted positively by stool butyrate and healthier plant forward diets
    Meeting Abstract

    Shah, U.; Derkach, A.; Adintori, P.; Cross, J.; Maclachlan, K.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Hassoun, H.; Tan, C.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2021)

    Fulltext@MSK | Save
  • Safety and effectiveness of weekly carfilzomib, lenalidomide, dexamethasone, and daratumumab combination therapy for patients with newly diagnosed multiple myeloma the MANHATTAN nonrandomized clinical trial
    Journal Article

    Landgren, O.; Hultcrantz, M.; Diamond, B.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Salcedo, M.; more...
    JAMA Oncology (2021)

    Fulltext@MSK | Save
  • Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m2) in combination with lenalidomide and dexamethasone
    Research Letter

    Korde, N.; Mastey, D.; Tavitian, E.; Mailankody, S.; Lesokhin, A.; Hassoun, H.; Smith, E. L.; Lendvai, N.; Hultcrantz, M.; Shah, U.; more...
    American Journal of Hematology (2021)

    Fulltext@MSK | Save
  • VRd versus KRd safety profiles in newly diagnosed multiple myeloma patients using real-world evidence data from a single institution: VRd has high rates of chronic neuropathy, and KRd has low rates of cardiopulmonary or renal toxicities when using optimized IV fluid management coupled with baseline cardiac workup
    Meeting Abstract

    Tan, C.; Diamond, B.; Hultcrantz, M.; Korde, N.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Lu, S. X.; Patel, D.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • A pilot study evaluating lenalidomide and CC-486 in combination with radiotherapy for patients with plasmacytoma (LENAZART study)
    Meeting Abstract

    Shah, U. A.; Werner, K.; Tavitian, E.; Devlin, S.; Mailankody, S.; Korde, N.; Hultcrantz, M.; Tan, C.; Lu, S. X.; Smith, E. L.; more...
    Blood (2020)

    Fulltext@MSK | Save
  • Weekly carfilzomib, lenalidomide, dexamethasone and daratumumab (wKRd-D) combination therapy in newly diagnosed multiple myeloma: final results from a clinical and correlative phase 2 study
    Meeting Abstract

    Landgren, O.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Tan, C.; Shah, U. A.; Lu, S. X.; Diamond, B.; Salcedo, M.; more...
    Blood (2020)

    Fulltext@MSK | Save